Literature DB >> 3548845

The isolation of human platelet factor V.

R W Viskup, P B Tracy, K G Mann.   

Abstract

Human platelet factor V has been isolated using either a monoclonal or polyclonal antibody directed against human plasma factor V. The largest peptide observed upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of purified human platelet factor V comigrates with purified human plasma factor V. However, a significant portion of the isolated protein is represented by peptides of lower apparent molecular weight (Mr). These lower Mr species that copurify with platelet factor V have been shown to be platelet factor V components by their immunological cross-reactivity with monoclonal and polyclonal antibodies to purified human plasma factor V. Platelets isolated from whole blood drawn directly into inhibitors to prevent proteolysis and platelet activation demonstrate the pattern of fragmented platelet factor V. The components of purified platelet factor V demonstrate apparent Mr ranging between 115 K and 330 K and are detectably different from the intermediates and end products observed during the thrombin cleavage of single-chain plasma factor V. Upon treatment with thrombin the platelet factor V components are cleaved and the end products are indistinguishable from those obtained upon thrombin activation of plasma factor V to plasma factor Va. Examination of the components by immunoblotting demonstrates that some of the cleavages which have occurred in the platelet factor V molecule are within the 150-K activation peptide. Bioassay indicates that platelet factor V exists as a procofactor and cleavage by thrombin yields the active cofactor, platelet factor Va. These data suggest that human platelet factor V is stored in the platelet as a partially fragmented procofactor that can be activated by thrombin to yield human platelet factor Va, the active cofactor in the human prothrombinase complex.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3548845

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  The Prothrombinase Complex: Assembly and Function.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-07       Impact factor: 2.300

3.  TFPIα interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation.

Authors:  Jeremy P Wood; Helle H Petersen; Bingke Yu; Xiaoai Wu; Ida Hilden; Alan E Mast
Journal:  Blood Adv       Date:  2017-12-26

4.  Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.

Authors:  Jeremy P Wood; Matthew W Bunce; Susan A Maroney; Paula B Tracy; Rodney M Camire; Alan E Mast
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

5.  Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.

Authors:  Jeremy P Wood; Lisa M Baumann Kreuziger; Umesh R Desai; Alan E Mast
Journal:  Br J Haematol       Date:  2016-06-15       Impact factor: 6.998

6.  Platelet-Derived Factor V Is a Critical Mediator of Arterial Thrombosis.

Authors:  Meiping Ren; Rong Li; Ni Chen; Ningbo Pang; Yongjie Li; Xin Deng; Liqun Wang; Mao Luo; Yan Liu; Haiyan Hao; Yong Liu; Hongmin Sun; Jianbo Wu
Journal:  J Am Heart Assoc       Date:  2017-07-03       Impact factor: 5.501

7.  Thrombin generation abnormalities in Quebec platelet disorder.

Authors:  Justin G Brunet; Tanmya Sharma; Subia Tasneem; Minggao Liang; Michael D Wilson; Georges E Rivard; Catherine P M Hayward
Journal:  Int J Lab Hematol       Date:  2020-08-06       Impact factor: 2.877

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.